<DOC>
	<DOC>NCT01839968</DOC>
	<brief_summary>The purpose of this ex-vivo study is to estimate the optimal platelet quantity necessary to reverse the antiplatelet effects of prasugrel.</brief_summary>
	<brief_title>Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel</brief_title>
	<detailed_description />
	<mesh_term>Blood Platelet Disorders</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Acute coronary syndrome Prasugrel loading dose 624h before inclusion Clopidogrel loading dose GPIIbIIIa use within 10 days before inclusion Known congenital thrombopathy and/or congenital coagulation defect</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>